Summit Therapeutics (SMMT) Return on Sales (2022 - 2025)
Summit Therapeutics' Return on Sales history spans 4 years, with the latest figure at 60.98% for Q1 2025.
- For Q1 2025, Return on Sales rose 4640.0% year-over-year to 60.98%; the TTM value through Mar 2025 reached 60.98%, up 2317.0%, while the annual FY2022 figure was 111.75%, 6277.0% down from the prior year.
- Return on Sales reached 60.98% in Q1 2025 per SMMT's latest filing, up from 37.71% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 60.98% in Q1 2025 to a low of 126.92% in Q3 2023.
- Average Return on Sales over 4 years is 27.95%, with a median of 5.12% recorded in 2022.
- Peak YoY movement for Return on Sales: crashed -4992bps in 2023, then surged 15991bps in 2024.
- A 4-year view of Return on Sales shows it stood at 4.34% in 2022, then crashed by -2825bps to 126.92% in 2023, then soared by 130bps to 37.71% in 2024, then surged by 62bps to 60.98% in 2025.
- Per Business Quant, the three most recent readings for SMMT's Return on Sales are 60.98% (Q1 2025), 37.71% (Q4 2024), and 32.99% (Q3 2024).